Dupilumab for Bullous Pemphigoid
Dupilumab is an effective and safe steroid-sparing treatment for adult bullous pemphigoid, with emerging evidence supporting its use either as monotherapy or in combination with reduced-dose corticosteroids.
Dosing Regimen
The standard dosing for bullous pemphigoid follows the atopic dermatitis protocol 1:
- Loading dose: 600 mg subcutaneously
- Maintenance: 300 mg subcutaneously every 2 weeks
This regimen has demonstrated robust efficacy across multiple case series and cohort studies. In the largest published series of 30 patients, 76.7% achieved complete clearance or marked response of blistering, with 83.3% showing complete or marked improvement in pruritus 2. A prospective cohort study showed median BPDAI scores dropping to 0 at week 4 when dupilumab was combined with corticosteroids 3.
Treatment Approaches
Monotherapy Strategy
Dupilumab can be used as monotherapy, particularly for patients where corticosteroids are contraindicated or poorly tolerated. A meta-analysis of 587 patients showed a 63% complete response rate with dupilumab monotherapy (without other systemic therapy) 4. However, one limitation: dupilumab monotherapy may be ineffective for oral mucosal lesions 5.
Combination Strategy (Preferred for Severe Disease)
For moderate-to-severe bullous pemphigoid, combining dupilumab with medium/low-dose corticosteroids is the optimal approach 5, 3. This strategy:
- Achieves disease control with significantly lower baseline and cumulative corticosteroid doses
- Reduces time to cessation of new blisters
- Shortens healing time and hospital stays
- Maintains efficacy equivalent to high-dose corticosteroid monotherapy but with superior safety 5
The combination approach allows for faster corticosteroid tapering—typically within 2-4 weeks patients show significant BPDAI reduction 6, 3.
Clinical Response Timeline
- Week 2: Eosinophil counts and IgE levels begin decreasing 3
- Week 2-4: Significant reduction in BPDAI scores, pruritus NRS, and cessation of new blister formation 6, 3
- Week 4: Many patients achieve BPDAI of 0 when combined with corticosteroids 3
- Week 8: Median time to disease control is 8 days in some cohorts 6
Maintenance and Long-term Use
Dupilumab monotherapy is highly effective for maintenance treatment with low relapse rates 3. A 12-month follow-up study demonstrated that patients maintained on dupilumab alone had significantly lower recurrence rates compared to corticosteroid monotherapy 3. This makes dupilumab particularly valuable as a long-term maintenance agent after initial disease control.
Safety Considerations
The safety profile is favorable with minimal serious adverse events:
Common Adverse Events
- Conjunctivitis (most common, typically mild and self-limited) 7
- Injection site reactions (3.3% in one series) 2
- Transient cognitive symptoms (rare) 6
Important Caveats
- No serious adverse events were reported across the major case series 2, 3
- Most adverse events do not require treatment discontinuation 4
- In a meta-analysis of 587 patients, only 112 adverse events were reported in 97 patients, with most being mild 4
Monitoring
While dupilumab does not require the extensive laboratory monitoring needed for traditional immunosuppressants, baseline assessment should include:
- Eosinophil count and percentage (expect reduction by week 2) 3
- Anti-BP180 antibody levels (useful for monitoring disease activity) 6, 3
- Ophthalmologic evaluation if conjunctivitis develops 7
Special Populations
Immune Checkpoint Inhibitor-Induced BP
Dupilumab is particularly valuable for ICI-induced bullous pemphigoid, where systemic corticosteroids may interfere with antitumor immunity. A case series of 4 patients showed sustained remission on dupilumab with continued ICI therapy, no BP relapse over 4 years, and no cancer progression 8.
Pregnancy/Breastfeeding
Limited data exist, but one case report describes successful use during breastfeeding for pemphigoid gestationis, though safety for breastfed infants remains under discussion 9.
Comparison to Traditional Therapy
Traditional first-line therapy for bullous pemphigoid involves high-potency topical corticosteroids (clobetasol propionate 10-40g daily) or systemic corticosteroids (prednisolone 0.5-1 mg/kg/day) 10. However, corticosteroid-related mortality and morbidity are substantial concerns, particularly in the elderly population most affected by BP 11, 12.
Dupilumab offers a paradigm shift: it provides comparable or superior efficacy while dramatically reducing corticosteroid burden and associated toxicity 5, 3. The ongoing LIBERTY-BP ADEPT trial (NCT04206553) will provide Level 1 evidence for dupilumab's efficacy, with primary endpoint being complete remission off steroids at week 36 13.
Practical Algorithm
- Confirm diagnosis: Clinical features, histopathology, direct immunofluorescence, anti-BP180 antibodies
- Assess severity: Use BPDAI score and extent of involvement
- Initiate treatment:
- Mild-moderate disease: Consider dupilumab monotherapy (600mg loading, then 300mg Q2W)
- Moderate-severe disease: Dupilumab + medium-dose corticosteroids (prednisolone 0.5mg/kg/day)
- Monitor response: Assess BPDAI, pruritus NRS, new blister formation at weeks 2 and 4
- Taper corticosteroids: Begin tapering at week 2-4 once disease control achieved
- Maintenance: Continue dupilumab monotherapy for sustained remission